OBJECTIVES: Rituximab maintenance therapy is associated with significant improvement in progression-free and overall survival in patients with NHL. However, treatment with rituximab causes considerable costs for health care systems. This article provides an overview of Pharmacoeconomical evaluations of rituximab and appraises their methodological quality. METHODS: A systematic literature search of cost-effectiveness studies on rituximab was carried out in several databases, such as PubMed, HTA databases and so on. Based on specified inclusion and exclusion criteria, cost-effectiveness studies were identified that compared standard chemotherapy with standard chemotherapy plus rituximab in patients with a subtype of NHL, including diffuse large B-cell lymphoma. The methodological quality of the studies was assessed using a quality checklist. RESULTS: The included researches are from several countries: the US, UK, Finland, France, Italy and so on. The average ICER in the UK is about USD$16318/QALY (GBP10173/QALY), $17688/QALY (EUR13275/QALY) in the EU and USD$22461/QALY in the US. All economic evaluations reported incremental cost-effectiveness ratios (ICERs) for the add-on therapy with rituximab that were below the country-specific thresholds, GBP20000~30000/QALY in the UK, EUR30000 ~50000/QALY in the EU and USD100000/QALY in the US. CONCLUSIONS: Although the cost of rituximab-related treatments are relatively higher, they are still cost-effective therapy based on the country-specific thresholds.